Co-founded Renibus Therapeutics as a Director of the company. Dr. Rasmussen has more than 25 years of experience in the pharmaceutical and biotech industries. Prior to joining Allakos, Dr. Rasmussen was the CMO at ZS Pharma, where he worked from 2010 to 2016. Prior to joining ZS Pharma, he was the President and CEO of Rasmussen Biotech & Pharma Consulting. Dr. Rasmussen has held the positions of Corporate Vice President, Head of Clinical Development, Medical & Regulatory Affairs at Novo Nordisk, and CMO, for Nabi Biopharmaceuticals and GenVec. He was the Senior Vice President for Clinical Research and Regulatory Affairs at British Biotech and Global Study Director for Cardiovascular Drug Development at Pfizer Central Research
Henrik S Rasmussen, MD, PhD
Dr. Rasmussen has led numerous global development programs and regulatory filings worldwide, including INDs, clinical trial applications (CTAs), NDAs, supplemental new drug applications (sNDAs), biologic license applications (BLAs), and MMA filings. He has published over 200 peer-reviewed papers in the therapeutic areas of Nephrology, Cardiology, Ophthalmology, Gastroenterology, Oncology, Gene Therapy, Diabetes and others.
Dr. Rasmussen received his MD and PhD from the University of Copenhagen, Denmark, and is trained in Internal Medicine and Cardiology.